Phibro Animal Health Corporation - Class A Common Stock (PAHC)
41.86
+0.67 (1.63%)
NASDAQ · Last Trade: Oct 30th, 10:57 PM EDT
Detailed Quote
Previous Close
41.19
Open
41.16
Bid
38.02
Ask
42.01
Day's Range
40.84 - 42.08
52 Week Range
16.16 - 42.82
Volume
218,552
Market Cap
1.27B
PE Ratio (TTM)
35.18
EPS (TTM)
1.2
Dividend & Yield
0.4800 (1.15%)
1 Month Average Volume
245,024
Chart
About Phibro Animal Health Corporation - Class A Common Stock (PAHC)
Phibro Animal Health Corporation is a global company that focuses on providing a wide range of animal health products and services. It develops, manufactures, and markets products aimed at improving the health and productivity of livestock and poultry, which includes vaccines, diagnostic tools, and nutritional products. By leveraging its expertise in science and technology, the company seeks to enhance animal well-being and optimize food safety and quality throughout the agricultural industry. Additionally, Phibro is committed to innovation and sustainability, striving to meet the evolving needs of farmers and the broader food supply chain. Read More
Phibro Animal Health Corporation is proud to announce the national launch of Restoris™ piezoelectric dental gel, a revolutionary dental gel designed to treat and support long-term oral health in dogs with periodontal disease. Developed in collaboration with a leading U.S. dental school and licensed to Phibro, Restoris represents a breakthrough in veterinary dental care, offering a dual mechanism of action to restore oral health at its foundation.
Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 6, 2025, at 9:00 AM Eastern Time.
Phibro Animal Health Corporation (Nasdaq: PAHC), a global leader in animal health and nutrition, today announced it has entered into a licensing agreement with Lighthouse Pharmaceuticals, Inc. for a novel therapeutic asset targeting periodontal health in companion animals.
Phibro Animal Health (PAHC) stock shows strong technical & fundamental momentum, meeting Minervini's Trend Template with high growth in earnings and sales.
Phibro shares soared nearly 18% after strong Q4 results beat estimates, driven by growth from the Zoetis MFA acquisition and solid full-year performance.
Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026.
Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2025 financial results on Wednesday, August 27, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 28, 2025, at 9:00 AM Eastern Time.
The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 24, 2025, to stockholders of record at the close of business on September 3, 2025.
